Supplemental Table 1.
Patient Characteristics at the Time of Hospital Admission for COVID-19, Stratified by Use of Famotidine
| Characteristics | Complete cohort |
After propensity score matching |
||||
|---|---|---|---|---|---|---|
| Famotidine (n = 84), n (%) | No famotidine (n = 1536), n (%) | P value | Famotidine (n = 84), n (%) | No famotidine (n = 420), n (%) | P value | |
| Age (y) | .39 | .51 | ||||
| <50 | 13 (15) | 320 (21) | 13 (15) | 57 (14) | ||
| 50–65 | 31 (37) | 483 (31) | 31 (37) | 184 (44) | ||
| >65 | 40 (48) | 733 (48) | 40 (48) | 179 (43) | ||
| Female sex | 39 (46) | 864 (56) | .63 | 39 (46) | 208 (50) | .60 |
| Race/ethnicity | .20 | .90 | ||||
| Hispanic | 25 (30) | 601 (39) | 25 (30) | 127 (30) | ||
| White, non-hispanic | 19 (23) | 336 (22) | 19 (23) | 82 (20) | ||
| Black, non-hispanic | 18 (21) | 322 (21) | 18 (21) | 102 (24) | ||
| Other | 22 (26) | 277 (18) | 22 (26) | 109 (26) | ||
| BMI, kg/m2 | .17 | .97 | ||||
| <25.0 | 15 (18) | 295 (19) | 15 (18) | 66 (16) | ||
| 25.0–29.9 (overweight) | 30 (36) | 388 (25) | 30 (36) | 157 (37) | ||
| ≥30 (obese) | 22 (26) | 434 (28) | 22 (26) | 110 (26) | ||
| Not recorded | 17 (20) | 419 (27) | 17 (20) | 87 (21) | ||
| Comorbidities | ||||||
| Diabetes | 24 (29) | 311 (20) | .07 | 24 (29) | 106 (25) | .52 |
| Hypertension | 29 (35) | 428 (28) | .19 | 29 (35) | 124 (30) | .36 |
| CAD | 9 (11) | 109 (7) | .21 | 9 (11) | 37 (9) | .58 |
| Heart failure | 7 (8) | 85 (6) | .28 | 7 (8) | 26 (6) | .47 |
| ESRD or CKD | 11 (13) | 130 (8) | .14 | 11 (13) | 47 (11) | .62 |
| Chronic pulmonary disorders | 2 (2) | 120 (8) | .07 | 2 (2) | 6 (11) | .52 |
| Initial oxygen requirement | .39 | .85 | ||||
| Room air | 25 (30) | 378 (25) | 25 (30) | 116 (28) | ||
| Nasal canula | 38 (45) | 678 (44) | 38 (45) | 187 (44) | ||
| Non-rebreather or similar | 21 (25) | 480 (31) | 21 (25) | 117 (28) | ||
BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; ESRD, end-stage renal disease.